Thymosin Alpha-1: Approvals, Evidence & the TB-500 Confusion

Common contexts

• Clinics may reference this peptide within broader wellness or longevity pathways.
• Use this directory page to compare profile transparency and consultation options.

Safety information

• This directory is informational and does not provide medical advice.
• Always discuss suitability and risk profile directly with a licensed clinician.

Clear intro

Thymosin alpha-1 sits in an unusual middle ground: a genuinely approved medicine across much of the world, an unapproved substance in the US and UK, and a molecule constantly confused with a WADA-banned relative. Pages that untangle that honestly earn trust.

Who this is for

This page is for people researching immune-support peptides, anyone confused about the thymosin family, and athletes who need the alpha-1 vs beta-4 anti-doping distinction spelled out.

What to ask before choosing a clinic

• Thymosin alpha-1 isn't approved here — what is your legal basis for offering it, as of today?
• The approval evidence is for hepatitis and adjunct immune support — what evidence supports the use you're proposing for me?
• Is your product from a licensed compounding pharmacy, and how is quality verified?

Pricing and red flags

Pricing without a clear, current answer on legality and sourcing is meaningless — in the US especially, the compounding position has changed twice in 2026.

• Selling it as a general immune booster for healthy people on the strength of foreign hepatitis approvals.
• Confusing or conflating it with TB-500 (thymosin beta-4).
• No clear answer on the current US compounding status or pharmacy sourcing.

What is Thymosin Alpha-1?

Thymosin alpha-1 is a peptide fragment originally isolated from thymus tissue, used medically as an immune modulator. Under the brand name Zadaxin it is an approved medicine in more than 35 countries — primarily for chronic hepatitis B, and in some markets for hepatitis C and as adjunct immune support in cancer care. It has never been FDA-approved in the United States or licensed by the MHRA in the United Kingdom. In the US it became one of the most contested molecules in the 2023–2026 peptide-compounding debate: reclassified into the restricted Category 2 in February 2026, then named days later in an HHS announcement as one of the peptides expected to return to legal compounding. Its practical US status should be checked at the time of reading.

How it works

Thymosin alpha-1 modulates immune function — it is described as enhancing T-cell function and acting on toll-like receptors, which underpins its use in chronic viral hepatitis and as adjunct therapy where immune function is suppressed. Those mechanisms are supported by its approved uses abroad; the leap from 'approved for hepatitis B in China and Italy' to 'general immune booster for healthy people' is where marketing outruns evidence.

Cost overview

Costs vary with the sourcing route, and in the US with the shifting compounding position. The meaningful questions are whether supply is from a licensed pharmacy and what monitoring accompanies it — not the vial price. See the peptide therapy cost guide.

What to expect from clinics

• A credible provider should distinguish thymosin alpha-1's real foreign approvals from its unapproved US/UK status — and from TB-500.
• Expect honesty that 'immune boosting' in healthy people is not what the approval evidence covers.
• In the US, expect a clear, current answer on compounding legality — the 2026 position has shifted twice.

Safety considerations

Thymosin alpha-1 has substantial clinical history in its approved markets and is generally reported as well tolerated in that context. That history applies to supervised medical use for approved indications — not to grey-market self-administration for wellness goals. Anyone considering it should involve a licensed clinician, confirm the current legal position in their country, and verify sourcing. This page does not recommend thymosin alpha-1 and does not provide dosing or administration guidance.

Compare this with semaglutide vs tirzepatide or move into city pages such as Los Angeles and New York if you want to compare how providers frame these treatments locally.